UBS/CALL/IDORSIA/3.502/0.5/20.09.24 Stock

YIDIOU

CH1292037012

Market Closed - Swiss Exchange 11:20:00 2024-07-11 am EDT
0.17 ^CHF	-5.56%

1 month	-41.38%
3 months	-45.16%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/3.502/0.5/20.09.24

Latest news about IDORSIA LTD

New semester, new state of mind	Jul. 01
Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment	Jul. 01	MT
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension	Jul. 01	GL
Idorsia Ltd Receives Approval from the European Commission for JERAYGO?	Jul. 01	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-11	0.17	-5.56%
24-07-08	0.18	-5.26%

Delayed Quote Swiss Exchange

Last update July 11, 2024 at 11:20 am EDT

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	YIDIOU
ISIN	CH1292037012
Date issued	2023-10-05
Strike	3.502 CHF
Maturity	2024-09-20 (71 Days)
Parity	2 : 1
Emission price	0.25 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.75 CHF
Lowest since issue	0.17 CHF
Delta	0.39x
Omega	2.753
Premium	78.33x
Gearing	7.11x
Moneyness	0.6088
Difference Strike	1.37 CHF
Difference Strike %	+39.12%
Spread	0.04 CHF
Spread %	23.53%
Theoretical value	0.1500
Implied Volatility	169.58 %
Total Loss Probability	84.95 %
Intrinsic value	0.000000
Present value	0.1500
Break even	3.802 CHF
Theta	-0.02x
Vega	0x
Rho	0x

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company

Ratings for Idorsia Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Consensus: Idorsia Ltd

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.132 CHF

Average target price

1.692 CHF

Spread / Average Target

-20.61%

Consensus